E. James Song, MD begins this session discussing the consequences of ineffective treatment of atopic dermatitis. Systemic therapy for atopic dermatitis should be considered for moderate-to-severe cases, when the atopic dermatitis affects special sites such as the hands, genitalia, and others, and/or when there is an impact on quality of life. Dr. Song goes on to differentiate the differences in short-term efficacy for systemic therapies for atopic dermatitis and highlights the fact that each patient may respond to therapies differently. Dr. Song also compares the responses to dupilumab with abrocitinib and upadacitinib as well as options for patients who do not respond to dupilumab. Jak inhibitors have demonstrated efficacy for treatment of atopic dermatitis, achieving faster and deeper levels of itch and skin response. There is, however, a boxed warning, require laboratory monitoring, and have higher risk of serious infections. Dr. Song concludes with a summary of the therapeutic options for atopic dermatitis and recommendations for which systemic agent to use.